Press Release

Sep 2, 2020
Cytox signs licence agreement with Cardiff University for polygenic risk score technology that is key to development of lead product genoSCORE(TM)

2nd September 2020: Oxford & Manchester, UK. Cytox Ltd, which provides non-invasive, risk assessment and patient stratification tools for Alzheimer's disease and dementia, has signed a license agreement with Cardiff University to access the University’s Intellectual Property regarding polygenic risk scoring algorithms for predicting the future onset of Alzheimer’s disease.

Under the terms of the licence, Cytox will gain exclusive commercialisation rights to intellectual property (IP) and know-how generated under its ongoing collaboration with Cardiff University. Additionally, Cytox will gain non-exclusive rights to further IP from Cardiff University.

Cytox is incorporating the technology defined within the licence in the development of genoSCORETM, a genetic risk assessment tool to identify people at risk of developing Alzheimer’s disease. genoSCORETM improves clinical trial patient recruitment enrichment to Alzheimer’s disease clinical studies; it also aids physicians in the management of patients in clinical practice. Cytox expects to launch genoSCORE as a product registered for professional use in the US and Europe, towards the end of 2020.

Dr Richard Pither, CEO of Cytox commented, “Cardiff University is one of the world-leading institutions developing polygenic risk scoring algorithms in neurological disorders. Following a successful collaboration funded by Innovate-UK, Cytox is very pleased to secure a licence agreement to allow further development and commercialisation of the technology. Cytox is committed to enabling improvements in clinical research and development, and future clinical practice in Alzheimer’s disease.”

 Professor Julie Williams, Centre Director, UK Dementia Research Institute Cardiff, said: "We are pleased to be working with CYTOX as the company seeks to identify individuals at risk of developing Alzheimer’s disease. It is important that we use our research findings to benefit clinical trial design, future clinical practice, and wider society."

 

Company contacts:

Cytox

Richard Pither – CEO

+44 1865 338 018

 

Media contact:

80th Atom

Adam Michael

+44 1223 511338

+44 777 588 1813

Adam@80thAtom.com

 

About Cytox

Without new drug therapies, the economic and healthcare cost burden of dementia - including Alzheimer's disease - is estimated to exceed $1tn per year in the next decade1.  Alzheimer’s – a highly complex disease with risk factors based in genetics, lifestyle, age, and environment – has seen no new approved drug therapy since 2003; and clinical trial failure rates run at 99.6%. Cytox’s products genoSCORETM and genoTORTM use Polygenic Risk Scoring (PRS) to improve clinical trial outcomes through patient stratification and the genetic characterisation of Alzheimer’s disease.

 

References:

1. World Alzheimer’s Report 2015 www.alz.co.uk/research/WorldAlzheimerReport2015.pdf